Literature DB >> 1651607

Human papillomaviruses in the pathogenesis of anogenital cancer.

H zur Hausen1.   

Abstract

Substantial experimental evidence accumulated over the past 8 years has indicated an etiological role for specific human papillomavirus (HPV) types in anogenital cancer and its premalignant precursors. Virus infection and viral gene expression emerge as necessary but obviously not sufficient factors for cancer induction. Additional modifications of host cell genes appear to be required for malignant progression of infected cells. The expression of viral oncoproteins in cells infected by "high-risk" types (e.g., HPV 16, HPV 18), in contrast to "low-risk" types (e.g., HPV 6, HPV 11), results in chromosomal instability and apparently in accumulation of mutational events. These "endogenous" modifications seem to be most important in the pathogenesis of premalignant lesions and tumor progression. Exogenous mutagens should act as additional cofactors.

Entities:  

Mesh:

Year:  1991        PMID: 1651607     DOI: 10.1016/0042-6822(91)90816-t

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  223 in total

1.  Production of human papillomavirus type 16 E7 protein in Lactococcus lactis.

Authors:  L G Bermúdez-Humarán; P Langella; A Miyoshi; A Gruss; R Tamez Guerra; Roberto Montes de Oca-Luna; Yves Le Loir
Journal:  Appl Environ Microbiol       Date:  2002-02       Impact factor: 4.792

2.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

5.  A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples.

Authors:  J H Nelson; G A Hawkins; K Edlund; M Evander; L Kjellberg; G Wadell; J Dillner; T Gerasimova; A L Coker; L Pirisi; D Petereit; P F Lambert
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

6.  Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer.

Authors:  E Guerrero; R W Daniel; F X Bosch; X Castellsagué; N Muñoz; M Gili; P Viladiu; C Navarro; M L Zubiri; N Ascunce
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

7.  Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus.

Authors:  H J Stauss; H Davies; E Sadovnikova; B Chain; N Horowitz; C Sinclair
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

8.  Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis.

Authors:  S Jeon; P F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.